Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AC Immune
Biotech
AC Immune cuts workforce by 30%, trims pipeline to preserve cash
The company is continuing to work with Johnson & Johnson and Takeda on active immunotherapies against Tau and amyloid-beta, respectively.
Nick Paul Taylor
Sep 4, 2025 10:27am
Potential new Alzheimer's drugs target tangles of tau
Sep 19, 2024 2:42pm
Researchers receive $6.9M NIA grant for tau-targeting drug
Aug 21, 2024 1:02pm
AC Immune sees 'landmark' potential in brain-penetrating ADC
Jul 31, 2024 10:00am
Takeda pays AC Immune $100M upfront for a ph. 2 Alzheimer's drug
May 13, 2024 5:51am
Roche’s Genentech returns Alzheimer’s assets to AC Immune
Jan 22, 2024 8:47am
